Program

Provisional Program

Please Click Here to download the current program timetable

Plenary Speakers

Dr Fred Tenover
Senior Director for Scientific Affairs, Cepheid. The United States of America.
Adjunct Professor in the Division of Epidemiology, Emory University, Rollins School of Public Health. The United States of America.
Consulting Professor of Pathology, Stanford University. The United States of America.,

Dr Rafael Cantón
Head of the Clinical Microbiology Department, University Hospital Ramón y Cajal. Spain
Associated Professor of Clinical Microbiolog, Complutense University of Madrid. Spain.

Professor John Turnidge
Clinical Director of Microbiology and Infectious Diseases, SA Pathology. Australia
Professor of Paediatrics, Pathology and Molecular and Biomedical Sciences. University of Adelaide. Australia.

Programme

Disclaimer
This program is correct at the time of printing, but organisers reserve the right to alter the program as deemed necessary.

Thursday, 24 February 2011

0900 - 1000 Plenary 1
USA300- Reflections on a Biological Success Story (Fred Tenover. Cepheid. The United States of America)

1000 - 1030 Morning Tea and Poster Session 1

1030 - 1200 Symposium 1
ST93 Community MRSA - Australia's Answer to USA300

  • Origin and Epidemiology of the Species (Graeme Nimmo. Queensland Pathology. Queensland)
  • Genome and Virulence (Ben Howden. Austin Health. Victoria)
  • Public Health Response and Infection Control Interventions in the Community (Keryn Christiansen. PathWest Laboratory Medicine - WA Royal Perth Hospital. Western Australia)

1200 - 1400 Industry Lunch-Time Symposium (TBC)

1400 - 1530 Proffered Papers Session 1
(six presentations)

1530 - 1600 Afternoon Tea and Poster Session 1
(Authors in Attendance)

1600 - 1730 Symposium 2
Carbapenem Resistance in Gram Negatives: The Role of the Carbapenemases

  • Mechanism and Detection (Rafael Cantón. University Hospital Ramón y Cajal. Spain)
  • Local and Overseas Epidemiology (Jan Bell. SA Pathology. South Australia)
  • Treatment and Control (Anton Peleg. Alfred Hospital. Victoria)

1730 - 1830 Annual General Meeting

1830 - 2000 Welcome Reception

Friday 25 February 2011

0900 - 1000 Plenary 1

  • Antibiotic Resistance Genes from the Environment. (Rafael Cantón. University Hospital Ramón y Cajal. Spain)

1000 - 1030 Morning Tea and Poster Session 2

1030 - 1200 Symposium 3
Multi Drug Resistance in the Community

  • Gram Negative Resistance (CTXM) (Joshua Freeman. Auckland District Health Board. New Zealand)
  • Management of MDR Gonorrhoea (Christopher Fairley. Melbourne Sexual Health Clinic. Victoria)
  • CA-MRSA (Kyra Chua. Austin Health. Victoria)

1200 - 1400 Industry Lunch-Time Symposium (TBC)

1400 - 1530 Proffered Papers Session 2
(six presentations)

1530 - 1600 Afternoon Tea and Poster Session 2
(Authors in Attendance)

1600 - 1730 Symposium 4
Clostridium difficile

  • Epidemiology (Tom Riley. University of Western Australia. Western Australia)
  • Laboratory Detection - Is PCR on its Own Good Enough? (Jenny Robson. Sullivan Nicolaides Pathologl. Queensland)
  • Treatment (Alistair McGregor. Royal Hobart Hospital. Tasmania)

1800 - 1930 Industry Reception

Saturday 26 February

0900 - 1000 Plenary 3
The Things that Bug Me: (John Turnidge. SA Pathology. South Australia)

1000 - 1030 Morning Tea and Poster Session 1

1030 - 1200 Symposium 5
Emerging Antimicrobial Resistance Worldwide

  • Newer Antimalarial Agents (Tim Davis. University of Western Australia. Western Australia)
  • Scabies and Pediculosis (James McCarthy. University of Queensland. Queensland)
  • Oseltamivir and the Flu (Allen Cheng. The Alfred Hospital. Victoria.)
  • Salmonella Typhi (Alan Street. The Royal Melbourne Hospital. Victoria)

1200 - 1300 Lunch

1300 - 1430 Pharmacy Workshop Session 1
Changes and Controversies to Antimicrobial Use

  • Practical Application to Recent Changes in Therapeutic Guidelines (Tony Korman. Monash Medical Centre. Victoria)
  • Aminoglycosides and Vancomycin Dosing - What's In and What's Out (Verna Wallroth. Peter MacCallum Cancer Centre. Victoria and Duncan McKenzie. Royal Hobart Hospital. Tasmania)
  • Antimicrobial Dosing in Continuous Renal Replacement Therapy (CRRT) (Jason Roberts. Royal Brisbane & Women's Hospital. Queensland.)

1430 - 1500 Afternoon Tea

1500 - 1630 Pharmacy Workshop Session 2
Anti-Infectives Prophlaxis

  • Prophylactic Anti-Infectives in Oncology/Haematology (Karin Thursky. Peter MacCallum Cancer Institute. Victoria)
  • Antibiotic Prophylaxis in Surgery (Morgyn Warner. SA Pathology. South Australia)
  • Post Exposure Prophylaxis in HIV. (Anna Pierce. Alfred Hospital. Victoria)

1200 - 1330 Lunch

1330 - 1500 Proffered Papers Session 3
(six presentations)

1500 - 1530 Afternoon Tea

1530 - 1700 CLSI vs EUCAST and Beyond

  • CLSI Pluses and Minuses (Fred Tenover. Cepheid. The United States of America)
  • EUCAST Pluses and Minuses (Rafael Cantón. University Hospital Ramón y Cajal. Spain)
  • What About Australia? (John Turnidge. SA Pathology South Australia.)

Pharmacy Workshop

The material in the Pharmacy Workshops (3 hours of content as Group-1 activity) has been accredited by SHPA as suitable for inclusion in an individual pharmacist's CPD plan as outlined in the SHPA CPD program at http://cpd.shpa.org.au/ The program addresses pharmacist competencies, including:

Competency Unit 1.2 Practise to accepted standards

Competency Unit 1.3 Pursue life-long professional learning and contribute to the development of others

Competency Unit 3.1 Participate in therapeutic decision making

Competency Unit 3.2 Provide on-going pharmaceutical management

Competency Unit 3.3 Promote rational drug use

Competency Unit 4.1 Assess prescriptions

Competency Unit 4.2 Evaluate prescribed medicines

Competency Unit 7.2 Evaluate and synthesise information

Competency Unit 7.3 Disseminate information

Dr Fred Tenover

Dr. Tenover received his Bachelors Degrees in Biology and Chemistry at the University of Dayton, and Masters and Doctoral degrees in Medical Microbiology from the University of Rochester. He was a Postdoctoral Fellow in Clinical Microbiology and Public Health at the University of Washington. After completing his post doctoral fellowship, he served as Chief of Molecular Biology and Associate Chief of Microbiology at the Seattle Veterans Affairs Medical Center in Seattle and was Associate Professor of Laboratory Medicine at the University of Washington.

Dr. Tenover went to the Centers for Disease Control and Prevention (CDC) in July 1990 as Chief of the Nosocomial Pathogens Laboratory Branch, and then became the Associate Director for Laboratory Science in the Division of Healthcare Quality Promotion. He established the CDC-World Health Organization Collaborating Centre for Global Monitoring of Antimicrobial Resistance in 1998 and served as its Director until 2008. In 2007, he became the Director of the Office of Antimicrobial Resistance at CDC.
In 2008, Dr. Tenover left CDC to become Senior Director for Scientific Affairs at Cepheid, in Sunnyvale, CA. He continues to serve as an Adjunct Professor in the Division of Epidemiology, Emory University, Rollins School of Public Health and is a Consulting Professor of Pathology at Stanford University in Palo Alto, California. He also is a Diplomate of the American Board of Medical Microbiology and a Fellow of both the American Academy of Microbiology and the Infectious Disease Society of America. He has been author/co author of over 300 per-reviewed journal articles and 40 book chapters and has edited 9 books

Dr Rafael Canton

Dr. Rafael Cantón is the Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal (Madrid, Spain) and is Associated Professor of Clinical Microbiology at Complutense University of Madrid. His clinical and research work is focussed on antimicrobial resistance mechanisms, cystic fibrosis pulmonary infections, and interplay of clonal epidemiology and resistance. He has published more than 200 articles in medical journals, 40 chapters in teaching books and communications on international congresses. He is also an active member of the European Society for Clinical Microbiology and Infectious Disease, member of the Steering Committee of EUCAST and Associated Editor of Clinical Microbiology and Infection journal and member of the editorial board of Journal of Clinical Microbiology.

Professor John Turnidge

Professor John Turnidge is Clinical Director of Microbiology and Infectious Diseases at SA Pathology, and Professor of Paediatrics, Pathology and Molecular and Biomedical Sciences at the University of Adelaide. He has worked in Microbiology and Infectious Diseases for more than 30 years, maintaining a strong interest in all things antimicrobial (from Petri dish to Patient). He is currently passionate about making improvements in susceptibility testing and contributes to this through various committees of the Clinical and Laboratory Standards Institute, and links to the European Committee on Antimicrobial Susceptibility Testing. When time permits, he is also passionate about Beethoven, Led Zeppelin, fine wine and fine food, and related indulgences, and in no particular order of preference.